Summit Therapeutics Inc. Expense From Share-based Payment Transactions With Employees
Summit Therapeutics Inc. (SMMT) reported Expense From Share-based Payment Transactions With Employees of GBP 646.00 thousand for the 11-month period ending 2019-12-31, per its 20-F filed 2020-04-30.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees · last filed 2020-04-30
- Summit Therapeutics Inc. expense from share-based payment transactions with employees for the quarter ending 2019-10-31 was 202.00K GBP, a 93.48% decline year-over-year.
- Summit Therapeutics Inc. expense from share-based payment transactions with employees for the quarter ending 2019-07-31 was 203.00K GBP, a 67.15% decline year-over-year.
- Summit Therapeutics Inc. expense from share-based payment transactions with employees for the quarter ending 2019-04-30 was 128.00K GBP, a 76.51% decline year-over-year.
- Summit Therapeutics Inc. expense from share-based payment transactions with employees for the quarter ending 2019-01-31 was 480.00K GBP, a 61.07% increase year-over-year.
| Period end | Expense From Share-based Payment Transactions With Employees 3 month | Expense From Share-based Payment Transactions With Employees 3 month as first filed | Expense From Share-based Payment Transactions With Employees 6 month | Expense From Share-based Payment Transactions With Employees 9 month | Expense From Share-based Payment Transactions With Employees 11 month | Expense From Share-based Payment Transactions With Employees 12 month |
|---|---|---|---|---|---|---|
| 2019-12-31 | 646.00K GBP 20-F · filed 2020-04-30 | |||||
| 2019-10-31 | 202.00K GBP 6-K · filed 2019-12-17 | 405.00K GBP derived: sum of 2 quarters · filed 2019-12-17 | 533.00K GBP 6-K · filed 2019-12-17 | 1.01M GBP derived: sum of 4 quarters · filed 2020-04-30 | ||
| 2019-07-31 | 203.00K GBP 6-K · filed 2019-10-11 | 331.00K GBP 6-K · filed 2019-10-11 | 811.00K GBP derived: sum of 3 quarters · filed 2020-04-30 | 3.91M GBP derived: sum of 4 quarters · filed 2020-04-30 | ||
| 2019-04-30 | 128.00K GBP 6-K · filed 2019-06-12 | 608.00K GBP derived: sum of 2 quarters · filed 2020-04-30 | 3.71M GBP derived: sum of 3 quarters · filed 2020-04-30 | 4.33M GBP derived: sum of 4 quarters · filed 2020-04-30 | ||
| 2019-01-31 | 480.00K GBP derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | 3.58M GBP derived: sum of 2 quarters · filed 2020-04-30 | 4.20M GBP derived: sum of 3 quarters · filed 2020-04-30 | 4.74M GBP 20-F · filed 2020-04-30 | ||
| 2018-10-31 | 3.10M GBP 6-K · filed 2019-12-17 | 3.72M GBP derived: sum of 2 quarters · filed 2019-12-17 | 4.26M GBP 6-K · filed 2019-12-17 | 4.56M GBP derived: sum of 4 quarters · filed 2020-04-30 | ||
| 2018-07-31 | 618.00K GBP 6-K · filed 2019-10-11 | 1.16M GBP 6-K · filed 2019-10-11 | 1.46M GBP derived: sum of 3 quarters · filed 2020-04-30 | 1.96M GBP derived: sum of 4 quarters · filed 2020-04-30 | ||
| 2018-04-30 | 545.00K GBP 6-K · filed 2019-06-12 | 500.00K GBP 6-K · filed 2018-06-05 | 843.00K GBP derived: sum of 2 quarters · filed 2020-04-30 | 1.34M GBP derived: sum of 3 quarters · filed 2020-04-30 | 1.88M GBP derived: sum of 4 quarters · filed 2020-04-30 | |
| 2018-01-31 | 298.00K GBP derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | 800.00K GBP derived: sum of 2 quarters · filed 2020-04-30 | 1.33M GBP derived: sum of 3 quarters · filed 2020-04-30 | 1.61M GBP 20-F · filed 2020-04-30 | ||
| 2017-10-31 | 502.00K GBP 6-K · filed 2018-12-11 | 1.03M GBP derived: sum of 2 quarters · filed 2018-12-11 | 1.31M GBP 6-K · filed 2018-12-11 | |||
| 2017-07-31 | 530.00K GBP 6-K · filed 2018-09-20 | 807.00K GBP 6-K · filed 2018-09-20 | ||||
| 2017-04-30 | 300.00K GBP 6-K · filed 2018-06-05 | |||||
| 2017-01-31 | 1.38M GBP 20-F · filed 2019-03-29 | |||||
| 2016-01-31 | 1.16M GBP 20-F · filed 2018-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |